Introduction: The IPO Market as a Barometer of US Stock Risk Appetite
Entering the third quarter of 2026, the US stock market is demonstrating mature and resilient toughness. After navigating macroeconomic turbulence and the tech giants' earnings season in the first half of the year, market attention is quietly shifting from zero-sum games to incremental capital narratives. As the most acute barometer of market risk appetite, the IPO (Initial Public Offering) market has shown significant signs of recovery recently after a period of relative quiet. For global investors focusing on "why choose US stocks," the IPO market's rebound is not just a sign of restored financing functions, but a concentrated reflection of the depth, liquidity, and innovative vitality of the US capital markets.
From a capital flow perspective, when secondary market valuation repairs hit a bottleneck, primary market premium expectations often become the new engine driving capital inflows. Several major IPOs in early August 2026 were not only successfully priced but also delivered stellar performances on their first trading day, directly warming overall market sentiment. In this in-depth analysis, we will start from the structural characteristics of the current US IPO market, explore the driving forces of the tech and biopharma sectors, and explain how this trend further cements the US stock market's position as a core global asset allocation.
1. Macro Environment Improvement: Fed Policy Expectations Stabilize and Liquidity Releases
IPO market activity never exists in isolation; it highly depends on macroeconomic liquidity and investor risk appetite. Mid-2026, US macroeconomic data showed a soft-landing characteristic of cooling without stalling. Inflation gradually approached the Fed's target range, and while the job market cooled slightly, it maintained a relatively steady pace of expansion. This macro environment provided the Fed with more flexible policy maneuvering room.
The market broadly expects the Fed's monetary policy to stabilize in the second half of 2026, with a possibility of marginal easing. The stabilization and decline of the 10-year US Treasury yield directly lowered the risk-free rate, reducing the opportunity cost of capital. For the primary market, a lower discount rate means higher present value for future cash flows, fundamentally improving valuation models for innovative companies. Additionally, as the Volatility Index (VIX) falls below its historical median, investor risk appetite rebounds, and capital begins to spill over from defensive sectors into highly elastic growth stocks and new listings.
2. Twin Engines: Tech's AI Application Layer and Biopharma's Commercialization Turning Point
This US IPO market rebound is not a broad-based rally, but shows typical structural divergence. Capital isn't blindly chasing all new stocks; it is highly concentrated in two sectors with clear profit paths and core technological barriers: tech and biopharma.
1. Tech Sector: Extending from Pick-and-Shovel to AI Application Layer
If 2023 to 2025 was the carnival of AI infrastructure (computing power, chips), 2026 is the year the AI application layer accelerates its landing. Several tech stars that recently filed for IPOs and successfully listed in early August are mostly concentrated in enterprise SaaS, AI vertical industry solutions, and edge computing. These companies leveraged open-source large models or partnered computing power to achieve commercial monetization in niche scenarios like medical diagnostics, industrial automation, and financial risk control.
From a US stock investment logic perspective, the secondary market's high valuations for pick-and-shovel players like Nvidia have begun to see divergence, and capital urgently needs to find the next Nvidia with tenfold growth potential. Therefore, AI application startups with real net dollar retention (NDR) over 120% and gross margins stable above 70% have become the most sought-after targets in this IPO market. This shift in investment logic from infrastructure to the application layer not only enriches the US tech sector ecosystem but also provides a new growth narrative for global capital.
2. Biopharma Sector: Resonance of Innovative Drug Commercialization Turning Points
Unlike the high-profile tech sector, the biopharma sector's IPO market performance is often more explosive but more hidden. In Q3 2026, multiple biotech companies with core pipelines (especially in ADC drugs, gene-editing therapies, and autoimmune diseases) successfully listed on Nasdaq. Behind this phenomenon is the significant reduction in financing costs for biotech companies after Fed rate expectations stabilized.
Furthermore, recent major US pharmaceutical companies facing patent cliffs have accelerated their M&A pace. This provides excellent exit expectations for small and medium-sized biotech companies. Investors realize that even if IPO companies have not yet achieved profitability, as long as their core pipelines show excellent Phase II or III clinical data, they are highly likely to be acquired at a premium by giants. Therefore, the boom in biotech IPOs is essentially a reflection of the perfect venture capital loop and M&A ecosystem in the US stock market.
3. Liquidity Feast and Institutional Advantages: Why Are US IPOs Still the Global Top Choice?
Against a backdrop of multiple global economic uncertainties, why do the world's top innovative companies still choose the US stock market as their preferred IPO destination? Behind this is not just a difference in capital scale, but a comprehensive victory in market system design.
1. Ultimate Liquidity and Valuation Premiums
The US stock market has the world's deepest capital pool and most diversified investor structure. From sovereign wealth funds and pensions to hedge funds, and the active retail investors in recent years, multi-layered market participants provide ample liquidity support for new listings on their first day. In contrast, IPOs in some European or Asian markets often face pricing discounts due to insufficient liquidity. In the US, as long as a company's narrative is compelling enough, the market is willing to give valuation premiums far higher than other markets. This liquidity premium is the core driving force attracting global companies to list in the US.
2. Perfect Institutional Investor Game Mechanism
The pricing mechanism for US IPOs is highly market-driven. The book-building process during the roadshow is not just a financing activity, but a deep game of corporate value among institutional investors. In this process, high-quality companies can screen for long-term value investors rather than short-term arbitrageurs. Additionally, the US market's strict information disclosure requirements increase compliance costs initially, but in the long run, build a bridge of trust between investors and companies, which is why the US market can continuously attract global capital.
3. Continuous M&A Ecosystem and Exit Channels
As mentioned earlier, the US market not only has strong IPO financing functions but also an active secondary market M&A and restructuring ecosystem. For venture capital and private equity funds, an IPO is often not the end, but the starting point for introducing public capital to further drive corporate growth, with the eventual possibility of being acquired by industry giants. This complete loop of venture capital, listing, and M&A makes the US the market with the smoothest global innovation capital circulation.
4. Capital Flow Tracking: From Defense to Offense, Retail and Institutions Resonate
Observing US capital flows since August 2026, we can clearly see a shift from defense to offense. According to market capital monitoring data, funds that continuously flowed into money market funds and high-dividend defensive sectors for several previous months have recently begun to show signs of marginal slowdown. At the same time, ETFs focusing on growth and small-cap stocks have started to see net inflows.
In this process, the power of retail investors cannot be ignored. With the popularization of zero-fee trading and fractional shares, retail investors' share in US stock pricing power has exceeded 40% for the first time. For the IPO market, retail participation not only increases first-day trading activity but also amplifies the brand effect of new stocks through social media and investment communities. Institutional investors, on the other hand, play the role of stabilizers during this phase, guiding new stock valuations back to rationality through the greenshoe mechanism and subsequent research coverage. This market structure where institutions and retail investors resonate is an important sign of the US stock market's prominent resilience.
5. Investment Strategy: How to Seize Opportunities and Avoid Risks During the IPO Rebound?
Although the IPO market rebound provides investors with a new source of excess returns, new stock investments are always accompanied by high volatility and uncertainty. For ordinary investors, participating in US IPO investments at the current stage requires following a strict trading strategy.
First, stick to fundamentals and beware of concept-riding. In the AI and biotech boom, there is no shortage of low-quality targets trying to ride the hype by changing company names or business descriptions. Investors should focus on the company's prospectus, paying attention to revenue growth, customer concentration, R&D expense ratios, and management track records. Truly valuable new stocks must have a clear technological moat and a quantifiable business model.
Second, use ETFs and IPO funds to diversify risk. The risk of a single IPO breaking its issue price is high for individual investors. By allocating to ETF products focused on the primary market or IPO subscriptions, one can enjoy the overall dividends of the new stock market while effectively diversifying the impact of a single black swan event.
Finally, set strict take-profit and stop-loss disciplines. US new stocks often have extremely high volatility in the early days of listing; first-day gains might even exceed 50%, but deep corrections may follow. Investors should avoid equating new stock investing with long-term value investing. During the high-volatility phase early on, one should strictly execute take-profit and stop-loss orders based on preset technical levels or valuation ranges to protect principal.
Conclusion: The Innovative Undertone and Allocation Value of the US Stock Market
The rebound of the US IPO market in Q3 2026 is by no means a simple cyclical bounce, but a microcosm of the US capital market's innovative vitality bursting forth again after macroeconomic tests. From the tech sector's deep evolution into the AI application layer to the biopharma sector's concentrated explosion at the commercialization turning point, the US stock market always stands at the forefront of global industrial transformation.
For global investors, the answer to the question of "why choose US stocks" is most vividly interpreted in the echoes of every new stock's bell-ringing ceremony. Because here lies not only the most mature risk pricing mechanism, but also the capital soil most tolerant of innovation. In the coming months, as more high-quality companies enter the capital markets, the breadth and depth of the US stock market will further expand, continuing to serve as the core engine of global wealth growth and leading the allocation direction of global capital. Angu Finance will continue to track the latest dynamics of the US IPO market for you, providing in-depth interpretations from a professional perspective to help you grasp the market's pulse.
